Safety in Lactation: Gastrointestinal antispasmodics

20 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. There is limited evidence for drugs…

Safety in Lactation: Drugs for urinary frequency, enuresis, and incontinence

25 September 2020This group of drugs have varied mechanisms of action in treating urinary control conditions. Indications are broadly similar for all drugs, although there are small…

Drug-induced hypersalivation – what treatment options are available?

1 August 2018This Medicines Q&A summarises published studies or case reports concerning the pharmacological treatment of drug-induced hypersalivation (drooling or sialorrhoea), particularly hypersalivation caused by clozapine. Update…
Search Articles

Medicine Compliance Aid Stability

Pro-BanthineArchimedes Pharma UK Ltd

Archimedes Pharma UK Ltd
Tablets s/c 15mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Protect from moisture
No special precautions for storage
4 November 2015

Lactation Safety Information

As GI antispasmodic

As GI antispasmodic
No published evidence of safety
Used in infants >1 month
Low levels anticipated in milk due to the drug’s properties
See summary for further information on anticholinergic affects
29 July 2020

For enuresis

For enuresis
Low levels anticipated in milk due to the drug's properties
No published evidence of safety
Monitor infant for anticholinergic effects, e.g. urinary retention, colic and constipation
29 July 2020